198 related articles for article (PubMed ID: 15374991)
1. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Ramírez de Molina A; Báñez-Coronel M; Gutiérrez R; Rodríguez-González A; Olmeda D; Megías D; Lacal JC
Cancer Res; 2004 Sep; 64(18):6732-9. PubMed ID: 15374991
[TBL] [Abstract][Full Text] [Related]
2. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
3. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
Ramírez de Molina A; Gutiérrez R; Ramos MA; Silva JM; Silva J; Bonilla F; Sánchez JJ; Lacal JC
Oncogene; 2002 Jun; 21(27):4317-22. PubMed ID: 12082619
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Hernández-Alcoceba R; Fernández F; Lacal JC
Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
[TBL] [Abstract][Full Text] [Related]
6. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.
Atlas E; Cardillo M; Mehmi I; Zahedkargaran H; Tang C; Lupu R
Mol Cancer Res; 2003 Jan; 1(3):165-75. PubMed ID: 12556556
[TBL] [Abstract][Full Text] [Related]
7. Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Huang C; Hydo LM; Liu S; Miller RT
Cell Signal; 2009 Dec; 21(12):1894-900. PubMed ID: 19716891
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells.
Lucas JJ; Domenico J; Gelfand EW
Mol Cancer Res; 2004 Feb; 2(2):105-14. PubMed ID: 14985467
[TBL] [Abstract][Full Text] [Related]
9. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells.
Mori N; Glunde K; Takagi T; Raman V; Bhujwalla ZM
Cancer Res; 2007 Dec; 67(23):11284-90. PubMed ID: 18056454
[TBL] [Abstract][Full Text] [Related]
10. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
11. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.
Glunde K; Jie C; Bhujwalla ZM
Cancer Res; 2004 Jun; 64(12):4270-6. PubMed ID: 15205341
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation.
Glunde K; Raman V; Mori N; Bhujwalla ZM
Cancer Res; 2005 Dec; 65(23):11034-43. PubMed ID: 16322253
[TBL] [Abstract][Full Text] [Related]
13. RbAp46 inhibits estrogen-stimulated progression of neoplastigenic breast epithelial cells.
Zhang TF; Yu SQ; Wang ZY
Anticancer Res; 2007; 27(5A):3205-9. PubMed ID: 17970062
[TBL] [Abstract][Full Text] [Related]
14. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
[TBL] [Abstract][Full Text] [Related]
15. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression.
Shekhar MP; Werdell J; Santner SJ; Pauley RJ; Tait L
Cancer Res; 2001 Feb; 61(4):1320-6. PubMed ID: 11245428
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
17. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.
Rodríguez-González A; Ramirez de Molina A; Fernández F; Lacal JC
Oncogene; 2004 Oct; 23(50):8247-59. PubMed ID: 15378008
[TBL] [Abstract][Full Text] [Related]
18. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.
Lucas L; Hernández-Alcoceba R; Penalva V; Lacal JC
Oncogene; 2001 Mar; 20(9):1110-7. PubMed ID: 11314048
[TBL] [Abstract][Full Text] [Related]
19. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
20. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.
Pampalakis G; Prosnikli E; Agalioti T; Vlahou A; Zoumpourlis V; Sotiropoulou G
Cancer Res; 2009 May; 69(9):3779-87. PubMed ID: 19383923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
